HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting thiol isomerase activity with zafirlukast to treat ovarian cancer from the bench to clinic.

Abstract
Thiol isomerases, including PDI, ERp57, ERp5, and ERp72, play important and distinct roles in cancer progression, cancer cell signaling, and metastasis. We recently discovered that zafirlukast, an FDA-approved medication for asthma, is a pan-thiol isomerase inhibitor. Zafirlukast inhibited the growth of multiple cancer cell lines with an IC50 in the low micromolar range, while also inhibiting cellular thiol isomerase activity, EGFR activation, and downstream phosphorylation of Gab1. Zafirlukast also blocked the procoagulant activity of OVCAR8 cells by inhibiting tissue factor-dependent Factor Xa generation. In an ovarian cancer xenograft model, statistically significant differences in tumor size between control vs treated groups were observed by Day 18. Zafirlukast also significantly reduced the number and size of metastatic tumors found within the lungs of the mock-treated controls. When added to a chemotherapeutic regimen, zafirlukast significantly reduced growth, by 38% compared with the mice receiving only the chemotherapeutic treatment, and by 83% over untreated controls. Finally, we conducted a pilot clinical trial in women with tumor marker-only (CA-125) relapsed ovarian cancer, where the rate of rise of CA-125 was significantly reduced following treatment with zafirlukast, while no severe adverse events were reported. Thiol isomerase inhibition with zafirlukast represents a novel, well-tolerated therapeutic in the treatment of ovarian cancer.
AuthorsJustine A Gelzinis, Melanie K Szahaj, Roelof H Bekendam, Sienna E Wurl, Megan M Pantos, Christina A Verbetsky, Alexandre Dufresne, Meghan Shea, Kaitlind C Howard, Oleg V Tsodikov, Sylvie Garneau-Tsodikova, Jeffrey I Zwicker, Daniel R Kennedy
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 37 Issue 5 Pg. e22914 (05 2023) ISSN: 1530-6860 [Electronic] United States
PMID37043381 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2023 Federation of American Societies for Experimental Biology.
Chemical References
  • Indoles
  • Phenylcarbamates
  • Sulfhydryl Compounds
  • zafirlukast
Topics
  • Animals
  • Female
  • Humans
  • Mice
  • Blood Platelets (metabolism)
  • Indoles
  • Ovarian Neoplasms (drug therapy, metabolism)
  • Phenylcarbamates (metabolism)
  • Sulfhydryl Compounds (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: